Effects of maternal pertussis vaccination on infant immune response
Phase 4
Completed
- Conditions
- 10004018<p>Maternal Vaccination Pertussis Boostrix</p>
- Registration Number
- NL-OMON22463
- Lead Sponsor
- ational Institute of Public Health and theEnvironment (RIVM)
- Brief Summary
ancet Infect Dis, vol 19, 2019, Barug et al.: https://doi.org/10.1016/S1473-3099(18)30717-5 Vaccine vol 38, 2020, Barug et al.: https://doi.org/10.1016/j.vaccine.2020.04.001
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 118
Inclusion Criteria
|
Zwangere vrouwen 18-40 jaar oud |
Exclusion Criteria
|
Het hebben gehad van een Pertusis vaccinatie in de afgelopen 5 jaar |
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Confirm superiority of IgG antibody levels against pertussis toxin (Ptx), present in the acellular vaccines, in infants at the age of 3 months of mothers having received a pertussis vaccine during pregnancy versus infants of mothers who have been vaccinated postpartum.</p><br>
- Secondary Outcome Measures
Name Time Method